Algert Global LLC Aldeyra Therapeutics, Inc. Transaction History

Algert Global LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.77 - $4.22 $43,405 - $66,127	15,670 New	15,670 $51,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $514,124 - $859,765	72,310 New	72,310 $607,000
Q1 2021 May 14, 2021	SELL	$6.53 - $14.42 $176,963 - $390,782	-27,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $14,280 - $26,882	3,570 Added 15.17%	27,100 $201,000
Q2 2020 Aug 12, 2020	SELL	$1.97 - $5.05 $13,632 - $34,946	-6,920 Reduced 22.73%	23,530 $98,000
Q1 2020 May 13, 2020	BUY	$1.62 - $6.4 $49,329 - $194,880	30,450 New	30,450 $75,000
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $131,594 - $182,620	-29,840 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $39,786 - $59,679	6,631 Added 28.57%	29,840 $179,000
Q1 2019 May 01, 2019	SELL	$7.14 - $9.85 $69,436 - $95,791	-9,725 Reduced 29.53%	23,209 $210,000
Q4 2018 Feb 01, 2019	BUY	$7.26 - $13.29 $239,100 - $437,692	32,934 New	32,934 $273,000
Q3 2018 Nov 14, 2018	SELL	$6.8 - $14.35 $70,883 - $149,584	-10,424 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$6.95 - $9.18 $72,446 - $95,692	10,424 New	10,424 $83,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $298M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.